Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
Tenax Therapeutics, Inc.NASDAQ: TENX
Short-term Debt · Q1 FY2026 · quarter ended Mar 2026
Short-term debt remains negative
Q1 FY2026 short-term debt was $0, compared with $0 a year earlier.
Context
- Short-term debt amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Short-term debt increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 500.9K | -19.8% |
| FY2022 | 2022-12-31 | 624.3K | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Debt vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's Mar 2026 short-term debt of $0 is the 4th highest of the 7 companies compared; the peer median is $320.5K.
- Short-term debt amounts to 0.0% of total assets for TENX, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $6.24M | +33.8% | -40.2% | 9.8% | |
| Mar 2026 | $744K | -94.2% | — | 1.9% | |
| Jun 2026 | $641K | — | +7.2% | 0.3% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding TENX) | $320.5K | -30.2% | -16.5% | 0.1% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.